Shares of Cassava Sciences (SAVA) were halted ahead of the company reporting that the Phase 3 REFOCUS-ALZ study of simufilam in mild-to-moderate AD did not meet each of the prespecified co-primary, secondary and exploratory biomarker endpoints and that Cassava will discontinue all efforts to develop simufilam for Alzheimer’s disease.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAVA:
- Cassava Sciences’ Alzheimer’s Drug Trials Fall Short, Neutral Rating Maintained Amid Uncertainties
- Cassava Sciences Amends Bonus Plan After Court Settlement
- H.C. Wainwright focused on what results from Cassava’s ReFocus-ALZ might reveal
- Cassava Sciences Reports 2024 Financial Results and Strategic Updates
- Cassava Sciences reports Q4 EPS (57c) vs (50c) last year
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue